|
BRAF-targeted therapy for locally advanced ameloblastoma of the mandible: A potential neoadjuvant strategy. |
|
|
Honoraria - Bristol-Myers Squibb/Medarex; Medison |
|
|
Honoraria - Bristol-Myers Squibb; Medison; MSD; Novartis |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; Medison; Merck Serono; MSD; Novartis; Roche; Sanofi |
Consulting or Advisory Role - Bristol-Myers Squibb; Medison; Merck Serono; MSD; Novartis; Nucleai; Roche; Sanofi |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Medison; Merck Serono; MSD; MSD; Novartis; Roche; Sanofi |
|
|
Honoraria - Bristol-Myers Squibb; Dexcel Pharma; Medison; MSD; Novartis; Roche |
|
|
Employment - 4c biomed; Ella Therapeutics |
Leadership - 4c biomed; Ella Therapeutics |
Stock and Other Ownership Interests - 4c Biomed; Biond Biologics; Ella Therapeutics; Nucleai; Purple Biotech; Staburo GmbH |
Honoraria - BMS; Medison; MSD; Novartis; Roche |
Consulting or Advisory Role - MSD; Novartis |
Speakers' Bureau - BMS; MSD |
Research Funding - Immunicom (Inst); Novartis (Inst) |
Patents, Royalties, Other Intellectual Property - Patent on anti-CEACAM1 blocking antibodies |
Travel, Accommodations, Expenses - BMS; MSD; Novartis |
|
|
Honoraria - AstraZeneca Canada; Bristol-Myers Squibb; Medison; MSD Oncology; NeoPharm; Novartis; Roche |
Consulting or Advisory Role - Clovis Oncology; MSD; Vascular Biogenics |
|
|
Honoraria - Bristol-Myers Squibb; MSD |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD |
|
|
No Relationships to Disclose |